19 05 2016Crede CG III, Ltd. v. 22nd Century Group, Inc.
Olshan client Crede CG III Ltd. filed a $250 million suit in New York federal court against 22nd Century, Inc.
rede CG III Ltd. filed a $250 million suit in New York federal court against 22nd Century, Inc., a genetic engineering company specializing in low-nicotine tobacco, for breach of contract and related claims.¬† Private equity fund Crede CG is the largest investor and alleges that, among other things, 22nd Century wrongfully excluded Crede from a lucrative Chinese joint venture formed to sell 22nd Century‚Äôs specialized tobacco products to the China National Tobacco Company, the largest global tobacco seller. In exchange for connecting 22nd Century to the opportunity and investing $10 million to help the company pursue the deal, Crede was to receive 22nd Century stock warrants and a 25 percent interest in the Chinese joint venture.¬† 22nd Century then deliberately sabotaged the joint venture by failing to make sensible efforts to secure long-term tobacco sales contracts with CNTC or any of its units, causing the joint venture to fail.¬† Crede is represented by litigation attorneys Thomas J. Fleming (Picture) and Brian A. Katz. Involved fees earner: Thomas Fleming - Olshan Frome Wolosky LLP; Brian Katz - Olshan Frome Wolosky LLP;
see all videos
Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr
Fintech, it’s described as the disruption in financial services pushed by consume
On October 14th, 2016, the world’s leading corporate stars aligned for a momentou
More than 19 Excellences in the global economy at the VI Annual Edition of IAIR AWARDS&
It took place on 19 November 2015 at Palace Downtown in Dubai the 19th edition of the I